Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2024-02-01 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份质押的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the pledge of shares by the controlling shareholder of the company. It details the number of shares pledged, the proportion of total shares, pledge start and end dates, and other related information. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about share pledging activity, which fits the category of a Regulatory Filing (RNS) as it does not fit into more specific categories like Capital/Financing Update (CAP) or Transaction in Own Shares (POS) since it is about pledged shares, not new financing or share repurchases. The document length is moderate and contains detailed disclosure, consistent with a regulatory announcement.
2024-02-01 Chinese
关于回购公司股份的进展情况公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase program. It details the number of shares repurchased, prices, total amount spent, and compliance with regulatory rules. It does not contain financial statements or comprehensive financial data but is an update on the company's share buyback activity. The document length is short (1318 characters) and focuses solely on the repurchase progress, fitting the description of a Transaction in Own Shares (POS) filing rather than a full financial report or other categories.
2024-02-01 Chinese
第三届监事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution from the first meeting of the third Supervisory Board of Enwei Pharmaceutical Co., Ltd. It details the election of the Supervisory Board Chairman and the meeting's compliance with company law and articles of association. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an official announcement related to board/management changes, specifically the election of a supervisory board chairman. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear content and context.
2024-01-29 Chinese
北京金杜（成都）律师事务所关于恩威医药股份有限公司2024年第一次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the procedural legality and validity of a company's 2024 first extraordinary shareholders' meeting. It details the convening, attendance, voting procedures, and results of the meeting, including election of board members and amendments to governance documents. The document does not contain financial statements or financial performance data, nor is it a presentation or announcement of financial results. It is a legal opinion on the conduct and outcomes of a shareholders' meeting, focusing on governance and procedural compliance. This fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports official voting results and validates the meeting's procedures and outcomes.
2024-01-29 Chinese
关于董事会、监事会完成换届选举并聘任高级管理人员、证券事务代表的公告
Board/Management Information Classification · 100% confidence The document is an announcement from a company about the completion of the board of directors and supervisory board re-election, as well as the appointment of senior management and securities affairs representatives. It details the composition of the new board, committees, and management personnel, their qualifications, and term durations. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes in the company's board and senior management personnel. Therefore, this document fits the category of Board/Management Information (MANG). The document length is about 4789 characters, which is consistent with a detailed announcement rather than a full report or a brief notice.
2024-01-29 Chinese
2024年第一次临时股东大会决议公告
Board/Management Information Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2024 first extraordinary general meeting (临时股东大会) of Enwei Pharmaceutical Co., Ltd. It includes information about the meeting's convening, attendance, voting results on board and supervisory committee elections, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the election of board members and supervisors, which is a change in the company's board of directors. The document is not a full annual or interim report, nor is it a simple announcement of a report publication. It is not a proxy solicitation or voting results announcement in isolation but a formal announcement of board/management changes resulting from the shareholder meeting. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is under 5,000 characters, but it contains substantive details of the board election results, not just a brief notice or link to a report, so it is not an RPA or RNS filing.
2024-01-29 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.